Sylentis Eyes Second Part of Phase I/II Trial for Glaucoma Rx, Searches for Partners | GenomeWeb

By Doug Macron

Having just wrapped up the first part of a phase I/II trial of its siRNA-based glaucoma therapy, Sylentis is on the lookout for a partnership deal that could help accelerate the drug candidate's development, a company official told RNAi News last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

A number of studies indicate that genes might influence political beliefs, Scientific American Mind reports.

Craig Venter's Human Longevity is deeply phenotyping individuals and capturing their genetic profiles to explore aging.

The San Francisco Business Times examines Verily's latest hires.

In Nature this week: comprehensive analysis of somatic mutations in breast cancer, and more.